

**Table S1.** Multivariate analyses of factors associated with reduced GFR including PNPLA3 recessive and additive model and unweighted GRS.

Panel A. Factors Associated with eGFR < 90 mL/min/1.73m <sup>2</sup>						
Variables	Model A		Model B		Model C	
	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)
BMI	0.97 (0.93–1.00)		0.97 (0.93–1.00)		0.97 (0.93–1.00)	
Metabolic Syndrome		1.56* (1.08–2.24)		1.56* (1.08–2.25)		1.58* (1.10–2.27)
FIB4-		0.85 (0.53–1.34)		0.87 (0.55–1.39)		0.87 (0.55–1.38)
PNPLA3 GG		0.73 (0.43–1.26)		-		-
PNPLA3				1.23 (0.85–1.77)		
GG vs. CC						
PNPLA3				0.81 (0.46–1.44)		
GG vs. CG						
Unweighted GSR						0.81 (1.02–1.17)

Model A: including BMI, metabolic syndrome, *PNPLA3* GG and FIB4-. Model B: including BMI, metabolic syndrome, *PNPLA3* GG vs. CG and *PNPLA3* GG vs. CG and FIB4-. Model C: including BMI, metabolic syndrome, unweighted GSR and FIB4-. \**p* < 0.05

**Table S2.** Multivariate analysis including age as covariate.

Panel A. Factors Associated with eGFR < 90 mL/min/1.73m <sup>2</sup>								
Variables	Univariable Analysis		Model A		Model B			
	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)		
PNPLA3 CG/GG	1.16 (0.83–1.63)		1.25 (0.87–1.81)		1.30 (0.90–1.87)		1.33 (0.92–1.93)	
Metabolic Syndrome		1.42* (1.00–2.00)		1.11 (0.75–1.64)		-		1.11 (0.75–1.64)
High blood pressure#		1.48* (1.01–2.15)		-		0.94 (0.62–1.44)		-
Arterial hypertension		1.47* (1.04–2.08)		-		-		0.90 (0.61–1.33)
Weighted GSR		1.24 (0.64–2.39)		-		-		1.45 (0.72–2.93)

**Panel B. Factors Associated with eGFR < 60 mL/min/1.73m<sup>2</sup>**

Variables	Univariable Analysis		Model A		Model B		Model C		Model D	
	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)
PNPLA3 CG/GG	0.98 (0.48–2.01)		0.80 (0.53–2.26)		1.14 (0.55–2.40)		1.18 (0.57–2.45)		-	
Arterial Hypertension		2.57* (1.09–6.06)		-		-		1.78 (0.72–4.39)		-
Weighted GSR		0.92 (0.23–3.65)		-		-		-		1.77 (0.45–6.95)

Model A: adjusted for age, BMI, metabolic syndrome, *PNPLA3* GG/CG and FIB4 -. Model B: adjusted for age, high blood glucose, high waist circumference, high blood pressure, low HDL cholesterol, high triglycerides, *PNPLA3* GG/CG genotype and FIB4 -. Model C: including arterial hypertension instead of high blood pressure, diabetes instead of high blood glucose, high waist circumference, low HDL cholesterol, triglycerides, age, *PNPLA3* GG/CG genotype and FIB4 -. Model D: adjusted for age, BMI, metabolic syndrome, weighted GRS and FIB4-. \* $p < 0.05$ ; # according to ATPIII modified criteria.


**Table S3.** Univariate correlation between age, MetS and arterial hypertension.

Variables	Metabolic Syndrome OR (95% CI)	Arterial hypertension OR (95% C.I.)
	Age	1.04 (1.02–1.05) <sup>°</sup>

<sup>°</sup> $p < 0.001$ .


**Table S4.** Propensity scores match of patient with *PNPLA3* GG and CC genotypes according to age, sex, metabolic syndrome and arterial hypertension.

Variables	<i>PNPLA3</i> GG (n = 64)	<i>PNPLA3</i> CC (n = 64)	p
Age (years)	53.0 ± 11.7	53.5 ± 10.6	0.816
Female (%)	43.8	40.6	0.720
Metabolic Syndrome (%)	46.9	46.9	1.000
Arterial Hypertension (%)	48.4	46.9	0.860
eGFR (mL/min/1.73m <sup>2</sup> )	93.7 (82.0–104.8)	94.6 (81.2–104.2)	1.000



**Figure S1.** Genotypes prevalence according to eGFR. Panel (A) shows prevalence of *PNPLA3* wild type (WT), heterozygous (He) and homozygous (Ho) according to eGFR cut-offs; Panel (B) shows prevalence of *MBOAT7* Wt, Hz and Ho according to eGFR cut-offs; Panel (C) shows prevalence of *TM6SF2* Wt, Hz and Ho according to eGFR cut-offs; Panel (D) shows prevalence of *GCKR* Wt, Hz and Ho according to eGFR cut-offs.


### A. eGFR < 90 mL/min/1.73m<sup>2</sup>



#### AUROC (95% C.I.)

Unweighted GRS 0.521 (0.472 — 0.570)  
Weighted GRS 0.530 (0.481 — 0.579)

### B. eGFR < 60 mL/min/1.73m<sup>2</sup>



#### AUROC (95% C.I.)

Unweighted GRS 0.518 (0.417— 0.620)  
Weighted GRS 0.504 (0.408 — 0.599)

**Figure S2.** ROC curve of unweighted and unweighted GRS for the detection of GFR <90 mL/min/1.73m<sup>2</sup> (**A**) and of GFR < 60 mL/min/1.73m<sup>2</sup> (**B**).